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Natural killer (NK) cells are part of the innate lymphoid cell (ILC) family and represent the
main cytotoxic population. NK cells develop from bone marrow common lymphoid prog-
enitors and undergo terminal differentiation in the periphery, where they finally gain their
cytotoxic competence as well as the ability to produce IFN-γ in response to engagement of
activating receptors.This process has been at least partially elucidated and several markers
have been identified to discriminate different NK cell stages and other ILC populations. NK
cell terminal differentiation is not only associated with progressive phenotypic changes
but also with defined effector signatures. In this essay, we will describe the phenotypic
and functional characteristics of the main stages of NK cell development and terminal
differentiation and discuss them in light of recent discoveries of novel ILC populations.
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NATURAL KILLER CELLS AND THE INNATE LYMPHOID CELL
FAMILY
Natural Killer (NK) cells are innate lymphocytes with the capa-
bility to rapidly kill virus-infected or transformed target cells
and to produce type 1 cytokines, such as IFN-γ. Over the past
years, other innate lymphoid effectors have been identified, which
share defined developmental requirements with NK cells, such
as the dependence on the transcriptional repressor inhibitor of
DNA binding 2 (Id2), but clearly differ for phenotype and effec-
tor properties. The heterogeneity displayed by the different innate
lymphocyte subsets closely resembles the one observed among
CD4+ T helper cells. Thus, a new nomenclature was adapted
to collectively define the family, which has been named innate
lymphoid cells (ILCs). According to this classification, ILCs have
been divided in three main groups: Group 1 ILCs, including NK
cells, are defined by the expression of the T-box transcription fac-
tors Eomesodermin (EOMES) and/or T-bet (TBX21) and produce
mainly IFN-γ in response to infected or transformed cells; Group
2 ILCs, expressing GATA3, produce IL-13 and IL-5 for the defense
against helminthic infections; Group 3 ILCs are characterized by
the expression of the orphan nuclear receptor transcription factor
RORγt (RORC) and include fetal lymphoid tissue-inducer (LTi)
cells and adult LTi-like cells, also named ILC3 (1). NK cells likely do
not represent the only member of Group 1 ILCs. Indeed, NK cells
residing in different organs, such as liver, lung, uterus, or intestine
are quite dissimilar among each other. It is still unclear whether
this peripheral heterogeneity originates from tissue-specific sig-
nals influencing either NK cell in situ development or terminal
differentiation. Alternatively, tissue resident NK cells might also
represent other Group 1 ILC members emerging independently
of NK cell precursors. In line with this hypothesis, other potential
Group 1 ILC members have been identified recently in the intes-
tine (2, 3). Hence, in the present review we will give an overview on
classical human NK cell development and terminal differentiation,
and discuss the current knowledge in the frame of this emerging
diversity of ILCs.
HUMAN NK CELL DEVELOPMENT
Natural killer cells develop during fetal life as well as after birth
from hematopoietic stem cells (HSCs) through a common lym-
phoid progenitor (CLP). Although most markers used in the
mouse and human systems are different, we will revise the major
findings of human NK cell development also in light of murine
data. Fetal as well as bone marrow (BM) CLP still have the poten-
tial to give rise to B, T, NK, and dendritic cells (DCs). As the
development of all mouse ILC group members relies on Id2, it was
proposed that a common Id2+ ILC progenitor might exist, but still
needs to be identified (4). Interestingly, fetal as well as BM HSC can
give rise to both, Group 3 ILCs and NK cells in mouse. In particular,
expression of the integrin α4β7 defines a mouse fetal CLP subset
with a developmental potential restricted to T, NK, and LTi (Group
3 ILC) cells (5, 6). In line with these data, mouse fetal liver α4β7+
CLP can up-regulate RORγt and differentiate toward LTi cells (7–
9). Similarly, after birth, mouse BM precursors expressing integrin
α4β7 and CXCR6 can give rise to Group 3 ILCs as well as to NK
cells, although with low efficiency, but have lost B cell as well as T
cell differentiation ability, thus potentially represent a common or
a mixture of progenitors committed toward Group 3 ILC and NK
cell lineage (8). However, it would be relevant to test the differen-
tiation potential of these cells toward Group 2 ILC, which can also
be generated from BM CLP (10–12). In humans, a pioneer study
from the group of Verneris has clearly shown that total umbilical
cord blood-CD34+ cells can give rise to both NK cells and Group
3 ILCs (13); however, these populations might originate from fetal
CLP, and the identification of a common human ILC progenitor
is not yet identified, similar to mouse. In addition to the CLP,
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mouse NK cell lineage committed progenitors have been initially
identified among Lin− CD122+ NK1.1− DX5− NK cells (14) and
more recently redefined according to the expression of CD27 and
CD244 or Id2 (15,16). Nevertheless, as to date it has not been tested
whether these cell populations are also able to differentiate toward
Groups 2 or 3 ILCs, it still remains to be formally proven whether
they represent or not the earliest NK cell committed precursor.
Although the exact phenotype is not yet completely established
in humans, CLP are enriched among CD34+ CD45RA+ CD38lo
CD10± CD7± cells. In particular CD34+ CD7+ CD45RA+ and
CD34+ CD10+ CD45RA+ cells are preferentially biased to develop
into T/NK and B cells, respectively (17–20). CLP-like cells with
NK cell commitment potential and expressing β7 integrin, simi-
lar to mice, have also been described in human peripheral blood
(PB) and shown to be enriched in extramedullary sites, such as
secondary lymphoid organs (SLOs) (21–23), which were there-
fore proposed as putative sites of human NK cell development.
According to this concept, human CLP-like CD34+ β7 integrin+
CD45RA+ (c-Kit− CD94−) cells identified in SLO still display T
cell and DC potential and have been termed “stage I” NK cells
(23). Human NK cell differentiation in SLO would then proceed
through “stage II” (CD34+ CD45RA+ c-Kit+ CD94−) and “stage
III” (CD34− c-Kit+ CD94−) NK cells, which would finally give
rise to “stage IV” NK cells, also defined as CD56bright CD16neg/lo
NK cells (23). More recently, it has been shown that most putative
“stage III” human NK cells (CD34− c-Kit+ CD94−) isolated ex
vivo in SLO are actually mature ILC3 (24, 25). As mature human
ILC3 mostly coexpress c-Kit and CD127, it was proposed that
among CD34− c-Kit+ cells only a minor fraction, characterized
by the lack of CD127 might represent “stage III” human NK cells
(25). Thus, due to the complex overlapping of markers between
human NK cells and ILC3, a more detailed analysis of in vitro
differentiation of “stage III” and “stage II” NK cell precursors
toward different ILC subsets would be of great help. Nevertheless,
these studies have contributed crucially to support the idea that
extramedullary compartments might indeed represent important
sites of NK cell development (22, 23). The unique milieu available
in different tissues might influence in situ differentiation of NK
cells and could actually explain the large phenotypic and func-
tional heterogeneity found among NK cells derived from different
tissues, such as liver, lung, or uterus. NK cell precursors might
migrate very early to the tissues and develop in situ influenced
by tissue-specific signals, such as cytokines, stromal or epithelial
cells, and environmental cues. However, we cannot exclude that
this large heterogeneity might actually rather reflect potentially
novel Group 1 ILC subsets, displaying NK-like phenotype. Along
this line, extramedullary compartments might represent preferen-
tial developmental sites not only for most Group 1 but also for
Group 3 ILCs. It has been shown that precursors of murine Group
3 ILCs do not up-regulate RORγt expression in the BM and might
migrate very early to the periphery, especially to the intestinal
lamina propria (LP), for their development/terminal differentia-
tion (8, 26). However, it still remains an open question at which
developmental stage (CLP? common ILC, Group 1 ILC, or NK cell
precursor?) NK cells migrate to peripheral tissues to undergo fur-
ther differentiation. Figure 1 illustrates markers associated with
early NK cell developmental stages derived from human CLP.
HUMAN NK CELL TERMINAL DIFFERENTIATION AND
RELATED EFFECTOR FUNCTIONS
Despite the presence of NK cells or NK cell-like populations in
different organs, most of our knowledge on NK cell biology orig-
inates from mouse splenic and human PB-derived NK cells. Even
within the same compartment, NK cells are heterogeneous, and
one possible interpretation of this observation is that this diver-
sity might reflect a process of terminal differentiation occurring
in the periphery. Along this line, different markers have been used
in humans and mouse to describe the stages of final NK cell mat-
uration. In mouse, several authors have contributed to delineate
a model in which splenic NK1.1+ NK cells can be mainly dis-
sected according to CD27 and CD11b, which enable to foresee the
following maturation progression: CD27− CD11b−→CD27+
CD11b−→CD27+ CD11b+→CD27− CD11b+ NK cells (27–
29). Conversely, most of the data concerning this process in
humans relies on the analysis of circulating PB-derived NK cells. In
this compartment, two main NK subsets were originally described
on the basis of the differential expression of CD56, which has no
homolog in mice and were named CD56bright and CD56dim NK
cells (30, 31). CD56bright and CD56dim NK cells differ in pheno-
type, functional capabilities, and preferential locations. CD56bright
NK cells are only a minority of PB-NK cells, whereas they represent
the majority of NK cells in SLO. CD56bright NK cells have been
described as preferentially CD62L−/lo CD94/NKG2A+ CD62Lhi
CD57− KIR− and commonly termed as the immunomodula-
tory subset, because of their potential to produce high levels of
cytokines like IFN-γ and TNF. In contrast, they express only very
low amounts of cytolytic granules and display poor cytotoxic capa-
bility. This feature is a characteristic of CD56dim NK cells, which
express high amounts of perforin and granzymes and are able to
kill target cells like virus-infected and transformed cells. How-
ever, the idea that CD56bright are the cytokine producers whereas
CD56dim NK cells represent the cytotoxic subset, might be actu-
ally misleading as both NK cell subsets can produce large amounts
of IFN-γ. CD56bright NK cells produce high amounts of IFN-γ
and extensively proliferate in response to DC-derived cytokines
like IL-2, IL-15, IL-12, and IL-18 (31), but are unable to produce
IFN-γ in response to target cell recognition (32, 33). Conversely,
CD56dim NK cells are less efficient in proliferating and produc-
ing IFN-γ in response to cytokines (31), but become the main
IFN-γ producers after target cell encounter (32, 33). A detailed
analysis of CD56dim functional properties and phenotype has
actually revealed a consistent heterogeneity also among CD56dim
NK cells. When CD56dim NK cells were dissected according to
the expression of either CD62L, CD94/NKG2A, or lack of CD57,
a subset of NK cells with intermediate phenotype and proper-
ties between CD56bright (CD94/NKG2Ahi CD62Lhi CD57−) and
CD56dim CD94/NKG2A–, CD62L–, or CD57+ cells could be iden-
tified (33–39). These data were also confirmed at global transcrip-
tome level (33). CD56dim NK cells displaying this intermediate
signature (CD94/NKG2A+, CD62L+, or CD57−) combine the
ability to produce IFN-γ and proliferate in response to cytokines,
characteristic for CD56bright NK cells, with the capacity to kill and
produce IFN-γ upon engagement of activating receptors (actRs),
typical of CD56dim NK cells. The developmental relationship
between CD56bright and the different CD56dim NK cell subsets
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FIGURE 1 | Schematic representation of human NK cell
development and terminal differentiation. The development of
human NK cells from a common lymphoid progenitor over NK cell
precursors to terminally differentiated NK cells is depicted from left to
right. The acquisition and loss of indicated surface markers and
functional properties propose a linear model of human NK cell
development and terminal differentiation. Protein expression levels are
depicted as black for high expression and white for no expression, gray
indicates intermediate levels. Functional properties are indicated
correspondingly. Abbreviations: common lymphoid progenitor (CLP),
bone marrow (BM), peripheral blood (PB), secondary lymphoid organs
(SLO). See also Ref. 59–61.
has been controversially discussed, but several studies support the
concept that CD56bright cells might represent the progenitors of
CD56dim NK cells. CD56bright NK cells display longer telomeres
compared to CD56dim NK cells and can acquire the expression of
CD16 and killer Ig-like receptors (KIR), as well as of other mark-
ers, in vitro as well as in vivo after transfer into immunodeficient
mice (33, 36). Further observations support a model of linear mat-
uration from more immature CD56bright toward terminally differ-
entiated CD56dim (CD94/NKG2A–, CD62L–, or CD57+) NK cells
passing through CD56dim NK cell subsets displaying intermediate
signatures (CD94/NKG2A+, CD62L+, or CD57–). As previously
mentioned, this phenotypic sequence is also associated with pro-
gressive loss of responsiveness to cytokines and gradual acquisition
of responsiveness to actR engagement (33–35) (Luetke-Eversloh
and Romagnani, unpublished data). The capability of the more
immature CD56bright and CD56dim NK cell subsets to respond
to cytokine stimulation strictly correlates to the expression of
CD94, CD62L, or CD57 and is reflected by higher expression of
cytokine receptors and STAT4 activation (33, 37, 39, 40). Con-
versely, the ability of the CD56dim subsets to kill and produce
IFN-γ in response to actR mainly correlates to the expression of self
MHC class I binding inhibitory receptors, in humans belonging
to the KIR family or CD94/NKG2A (41–44). This phenomenon,
termed education or licensing, was originally described in mice for
NK cells expressing self MHC class I specific inhibitory Ly49 recep-
tors or CD94/NKG2A (41–43). According to this concept, during
their differentiation or the course of immune responses, NK cells
are licensed by self MHC class I molecules through engagement
of their inhibitory receptors and this interaction results in NK
cell functional competence in response to actR. Thus, licensed NK
cells are not only functionally competent but also tolerant because
they display at least one inhibitory receptor for self MHC. Con-
versely, NK cells which do not have a self MHC-specific inhibitory
receptor are less functional and therefore still tolerant toward self
(41, 45–47). The molecular mechanisms underlying this process
have been only partially clarified. In mice, NK cell education seems

























































Luetke-Eversloh et al. Human NK cell differentiation
to require functional immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) of self MHC class I binding Ly49 receptors, but to
be independent of SHP-1 signaling (41–43). In addition, educated
mouse NK cells have an altered membrane distribution of actR,
which is instrumental to functional competence in response to
actR engagement (41, 45–47). Although further research is needed
to clarify the site, the stimuli, and the time of NK cell education, it
is now clear that this process is not an on-off switch occurring dur-
ing BM development, but rather a fine tuning determined by the
number and the affinity of MHC-inhibitory receptor interactions
(41, 45–48). However, the stage of NK cell terminal differentia-
tion might also contribute to finely tune functional competence
in response to actR engagement. Terminally differentiated NK cell
subsets are enriched in cells expressing more than one inhibitory
receptor (39), and thus in educated cells, suggesting that differenti-
ation and education might not be entirely uncoupled processes. In
Figure 1, we summarized several markers defining the phenotype
and functions of the different NK cell subsets.
In contrast to individual markers, the combination of expres-
sion of CD16, KIR, CD57, CD62L, CD94/NKG2A does not identify
three main populations but results in a complex number of inter-
mediate, terminally differentiated, educated, and non-educated
NK cell subsets. Although this implies even a larger heterogeneity
of PB-NK cells, it does not exclude that NK cell terminal differen-
tiation still proceeds following a linear progression. In support of
this model, we have observed that these markers are not acquired
or lost synchronously in time during reconstitution from HSC
during transplantation and this might contribute to explain NK
cell peripheral variety (M.K. and C.R., unpublished data). More-
over, diverse signals, such as homeostatic and pro-inflammatory
cytokines or engagement of defined activating or inhibitory recep-
tors at steady state or during infections, might influence NK cell
terminal differentiation and/or education and determine the qual-
ity and the intensity of this process. One clear example of how
environmental stimuli can dramatically poise human NK cell final
maturation is cytomegalovirus (CMV) infection, which can glob-
ally accelerate NK cell terminal differentiation (49). CMV infection
induces the expansion and persistence of a unique NK cell sub-
set, expressing the actR NKG2C and being preferentially positive
for CD57 and self MHC class I binding KIR (50–52). Although
NKG2C+ NK cells undergoing expansion during CMV infection
tend to resemble phenotypically and functionally terminally dif-
ferentiated NK cells, it has been also suggested that they might
represent the human correspondent of the previously described
Ly49H+ memory-like murine NK cells expanding and persisting
after CMV infection (53, 54) (Figure 1). Interestingly, expansion of
NKG2C+ NK cells occurs also in CMV-seropositive patients with
chronic hepatitis B or C virus or during hantavirus infection (55,
56). Further experiments are required to understand their origin
and developmental relationship with other PB-NK cell subsets.
Interestingly, different stages defined according to CD16,
NKG2A, and KIR can also be identified among fetal NK cells,
suggesting that similar forces likely govern the process of dif-
ferentiation before and after birth. However, even in fetal lung
where NK cells are strongly enriched in more mature KIR+ cells,
CD57 expression is very low and only NKG2A, but not self MHC
specific KIR, mediate NK cell education, possibly suggesting that
fetal tissue milieu influence NK cell differentiation and functional
properties (57).
Despite of all these suggestive evidences, it is however difficult to
completely exclude that human NK cell peripheral heterogeneity
might not rather represent developmentally unrelated members
of the Group 1 ILC family. CD56bright NK cells uniquely express
CD127, CD117, and GATA3, which are hallmarks of other ILC
subsets and have been also proposed to correspond to mouse
thymus-derived NK cells (58). Further investigation employing
different experimental approaches might help us to revisit this
issue and elicit some surprises.
“It’s a rare occasion when your plans and expectations come
down just exactly how you planned them. Who can say, anyway?
Time will tell” (“Time will tell,” Tower of Power).
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